Supp Figures from Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy

التفاصيل البيبلوغرافية
العنوان: Supp Figures from Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
المؤلفون: Mark L. Bagarazzi, Cornelia L. Trimble, David B. Weiner, Stanley Plotkin, J. Joseph Kim, Niranjan Y. Sardesai, Laurent Humeau, Amir S. Khan, Russell Vang, Jian Yan, Jean D. Boyer, Dawson Knoblock, Michael Dallas, Albert J. Sylvester, Kimberly A. Kraynyak, Matthew P. Morrow
بيانات النشر: American Association for Cancer Research (AACR), 2023.
سنة النشر: 2023
الوصف: Supplemental Figure 1 - Rates of CIN2/3 regression (primary endpoint) or CIN2/3 regression concomitant with clearance of HPV16 and/or HPV18 infection (secondary endpoint) in the Per Protocol population of the Phase IIb study of VGX-3100 for the treatment of biopsy proven CIN2/3 with documented HPV16 and/or HPV18 infection. Supplemental Figure 2 - Immunohistochemical analysis of CD8 infiltration at study start. The left panel shows the frequency of CD8 positive cells/mm2 as broken out by achievement of the primary endpoint of histopathological regression of CIN2/3 to CIN1 or WNL. The right panel shows the frequency of CD8 positive cells/mm2 as broken out by achievement of the primary endpoint of histopathological regression of CIN2/3 to CIN1 or WNL concomitant with elimination of HPV16/18 infection. Supplemental Figure 3 - CD137 is a marker for antigen specificity and activation on CD8+ T cells. A representative patient stain is shown for CD137 expression prior to (top) and following dosing (bottom) with VGX-3100. Whole unfractionated PBMCs were incubated with DMSO (vehicle control), OVA peptide (peptide control) HPV16 antigens, HPV18 antigens or Concanavalin A (positive control) for 120 hours. Supplemental Figure 4 - Breakdown of HPV16 and HPV18 positivity at enrollment of the study. Patients are represented as being HPV16 positive only (HPV16+ and HPV18-), HPV18 positive only (HPV16- and HPV18+) or positive for both viruses (HPV16+ and HPV18+). The bottom row represents the total patients in the study. Columns are broken into placebo and VGX-3100 cohorts and total patients in the study.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aba4a17eb58c63a1341c4b673bd3881
https://doi.org/10.1158/1078-0432.22467135.v1
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....1aba4a17eb58c63a1341c4b673bd3881
قاعدة البيانات: OpenAIRE